IDO1 and melanoma: Specifically, we highlight the development cycle starting from tracer synthesis (11C-l-1MTrp) and biomarker identification (IDO1 in the mesenteric lymph nodes (MLNs)) to biomarker validation in a mouse model of melanoma treated with different immunotherapy regimens.